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Abstract
Defining the precise cellular mechanisms of neutralization by potently inhibitory antibodies is important for understanding
how the immune system successfully limits viral infections. We recently described a potently inhibitory monoclonal
antibody (MAb E16) against the envelope (E) protein of West Nile virus (WNV) that neutralizes infection even after virus has
spread to the central nervous system. Herein, we define its mechanism of inhibition. E16 blocks infection primarily at a post-
attachment step as antibody-opsonized WNV enters permissive cells but cannot escape from endocytic compartments.
These cellular experiments suggest that E16 blocks the acid-catalyzed fusion step that is required for nucleocapsid entry
into the cytoplasm. Indeed, E16 directly inhibits fusion of WNV with liposomes. Additionally, low-pH exposure of E16–WNV
complexes in the absence of target membranes did not fully inactivate infectious virus, further suggesting that E16 prevents
a structural transition required for fusion. Thus, a strongly neutralizing anti–WNV MAb with therapeutic potential is potently
inhibitory because it blocks viral fusion and thereby promotes clearance by delivering virus to the lysosome for destruction.
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Introduction
Neutralizing antibodies can inhibit virus infection by impeding
one of several critical steps of the virus lifecycle. These include
blocking attachment to the cell surface, interaction with host
factors required for internalization, and structural transitions on
the virion that drive membrane fusion (reviewed in [1,2]).
Antibodies can independently neutralize virus infection by
promoting virus aggregation, destabilizing virion structure, and
blocking budding or release from the cell surface (reviewed in [3]).
Historically, many of the most potently neutralizing antibodies
inhibit infection by interfering with required interactions between
viruses and obligate cellular receptors (e.g., rhinovirus and ICAM-
1, HIV and CD4 or CCR5, and poliovirus and CD155).
West Nile virus (WNV) is a mosquito-borne positive polarity
RNA virus of the Flavivirus genus within the Flaviviridae family.
Similar to other Flaviviruses, such as Dengue (DENV), yellow
fever, and Japanese encephalitis viruses, WNV has an ,11 kb
RNA genome that encodes three structural (C, prM/M and E)
and seven non-structural (NS1, NS2a, NS2b, NS3, NS4a, NS4b,
and NS5) proteins that are generated by cleavage from a single
polyprotein [4,5]. WNV has spread globally and epidemic
outbreaks of encephalitis now occur annually in the United States.
Infection with WNV causes syndromes ranging from a mild febrile
illness to severe neuroinvasive disease and death [6,7]. There is
currently no approved vaccine or therapy for WNV infection.
Structural analysis of the WNV and DENV virions by cryo-
electron microscopy [8,9] reveals a ,500 A ˚ mature virion with a
smooth outer surface. The 180 copies of the E glycoproteins lay
relatively flat along the virus surface as anti-parallel dimers in three
distinct symmetry environments. Following exposure to low pH in
the endosomal compartment, the E proteins rearrange from
homodimers to homotrimers, exposing a fusion peptide, which
interacts with the endosomal membrane and allows uncoating and
nucleocapsid escape into the cytoplasm [10].
The atomic structure of the surface E glycoprotein has been
defined by X-ray crystallography for DENV, WNV, and tick-
borne encephalitis virus (TBEV) [11–15], revealing three con-
served domains. Domain I (DI) is a 10-stranded b-barrel and
forms the central structural architecture of the protein. Domain II
(DII) consists of two extended loops projecting from DI and
contains the putative fusion loop (residues 98–110), which
participates in a type II fusion event [10,16,17]. In the mature
virus, the fusion loop packs between two anti-parallel dimers and is
solvent inaccessible, protecting the virus from premature fusion
and inactivation. Domain III (DIII) is located on the opposite end
of DI, forms a seven-stranded immunoglobulin-like fold, and has
been suggested as a receptor binding site [18–20].
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mice lacking B cells are highly vulnerable to lethal infection [21].
During infection with flaviviruses, most neutralizing antibodies are
directed against the E protein, although a subset binds the prM
protein [22,23]. To better understand the structural basis of
antibody protection against WNV, we recently generated a large
panel of monoclonal antibodies (MAbs) against WNV E protein
[24]. One antibody, E16, was observed to block WNV infection in
vitro and in vivo and was effective as a post-exposure therapy even5
days after infection [24,25]. Potent E16 neutralization occurs with
strikingly low stoichiometric requirements, as a virion occupancy of
,25% is sufficient to inhibit infection [26]. Herein, we determine
the mechanism by which this therapeutic MAb neutralizes WNV
infection. E16 traffics with WNV particles into permissive target
cells, and is strongly inhibitory because it blocks pH-dependent
fusion, a critical step in the entry pathway of this virus.
Results
MAb E16 does not block WNV entry
A common mechanism of antibody-mediated neutralization of
viral infection is to prevent attachment and entry into target cells.
Previously published studies suggested that E16 did not dramat-
ically reduce WNV binding to Vero cells but instead inhibited at a
post-attachment step [27]. To gain further insight as to how E16
inhibits infection, WNV was pre-incubated with Alexa-488
conjugated E16 or E53, a second inhibitory MAb that binds to
the fusion loop in DII, prior to a cell binding assay at 4uC.
Subsequently, cells were washed at 4uC, fixed and visualized by
confocal microscopy. At 4uC, enveloped viruses, including
flaviviruses, remain on the cell surface and are not internalized
[28–30]. As expected, in the absence of WNV, labeled E16 and
E53 were not visualized on the surface or interior of cells (data not
shown). When Alexa-488-E53-WNV complexes were added, no
fluorescence signal was observed on the surface of Vero cells
(Figure 1A, panels F and H), suggesting that E53, as hypothesized
previously [27], primarily inhibits WNV attachment to Vero cells.
Similar results were obtained with Alexa-488 conjugated E60, a
MAb that binds to a similar epitope as E53 in DII (data not
shown). In contrast, staining was apparent on the surface of cells
incubated with labeled Alexa-488-E16-WNV complexes. Thus,
despite saturating and neutralizing concentrations (100 mg/ml) of
E16 MAb, WNV binding to Vero cells still occurred (Figure 1A,
panels B and D). Analogous results were obtained with the strongly
neutralizing DIII-specific E24 MAb (data not shown).
To determine if the E16 MAb restricted virus entry, Vero cells
were warmed to 37uC after MAb-WNV complex pre-binding at
4uC, and again visualized by confocal microscopy. As anticipated,
Alexa-488-E53-WNV complexes were not detected inside cells
(Figure 1A, panels N and P). In contrast, Alexa-488-E16-WNV
complexes readily entered cells and accumulated in acidic vesicles
that were identified with a pH sensitive dye (Figure 1A, panels J
and L). Even after several hours of incubation, E16-WNV
complexes remained localized in these acidic cellular compart-
ments (Figure 1B, panels B–D), whereas E53-WNV complexes
were not detected within the cells (Figure 1B, panels F–H). In
contrast, in the absence of neutralizing antibodies, WNV infection
progresses rapidly as demonstrated by the accumulation of E
protein in the cell over time (Figure S1).
E16 blocks infection in a manner analogous to inhibiting
endosome acidification
Because E16-WNV complexes co-localized with an acidified
intracellular compartment for several hours, we hypothesized that
this MAb prevented virus fusion with endosomal membranes.
Because WNV infection requires a pH-dependent structural
rearrangement of E proteins for fusion, we evaluated whether
concanamycin A1, a vacuolar-ATPase inhibitor [31], blocked
WNV infection at a similar cellular stage as did E16. Vero cells
were infected at a high multiplicity of infection (MOI) in the
presence of 10 nM concanamycin A1 or humanized E16 (hu-
E16, 100 mg/ml) or a media control for 3 h or 24 h at 37uC.
Cells were washed, fixed, and stained for WNV using an
oligoclonal pool of mouse MAbs against the E protein. Samples
treated with hu-E16 were also stained with an anti-human IgG
secondary antibody to confirm that hu-E16 co-localized with the
virus. In the absence of concanamycin A1 or hu-E16, infected
Vero cells showed strong staining of E protein at 3 h that was
markedly increased at 24 h (Figure S1). Treatment with 10 nM
concanamycin A1 resulted in a punctate pattern of E protein
staining at 3 and 24 h, suggesting that WNV localized to and
likely remained sequestered in endocytic compartments (Figure 2,
panels A and D). Analogous to treatment with concanamycin A1,
hu-E16-opsonized WNV showed a similar staining pattern up to
24 hours after infection (Figure 2, panels B and E). As co-staining
of oligoclonal mouse anti-E protein and hu-E16 was observed
over time, it is likely that E16 was still bound to WNV, and these
virus-MAb complexes accumulated in endosomal/lysosomal
compartments (Figure 2, panels C and F). Of note, in
Figure 2C, only a subset of the blue spots (which indicates the
presence of the virion) co-stain with hu-E16. This is likely a
sensitivity of detection issue as E16 neutralizes infection at both
low (,25% or 30 copies per virion) and high occupancy [26].
Because of the high MOI used, some viruses will be more
completely decorated (and thus fluorescent), whereas others will
bind fewer antibodies yet still be neutralized. Virions that bind
fewer E16 antibodies yet still are neutralized may co-stain less
brightly in this microscopic assay.
E16 blocks fusion at the plasma membrane
The ability of E16 to block WNV egress from endosomes
suggested that this MAb directly inhibited the pH-dependent
fusion step. Initially, to test this, we used a surrogate plasma
membrane fusion infection assay that has been validated for
alphaviruses and flaviviruses [32,33]. Normally, flaviviruses enter
cells via receptor-mediated endocytosis, with fusion occurring from
within acidic endosomes [29,34,35]. However, flaviviruses also can
be induced to fuse directly with the plasma membrane, at low
efficiency, when cell-bound virus is exposed to an acidic solution
Author Summary
Antibodies are essential components of the immune
response against many pathogens, including viruses. A
greater understanding of the mechanisms by which the
most strongly inhibitory antibodies act may influence the
design and production of novel vaccines or antibody-
based therapies. Our group recently generated a highly
inhibitory monoclonal antibody (E16) against the envelope
protein of West Nile virus, which can abort infection in
animals even after the virus has spread to the brain. In this
paper, we define its mechanism of action. We show that
E16 blocks infection by preventing West Nile virus from
transiting from endosomes, an obligate step in the entry
pathway of the viral lifecycle. Thus, a strongly inhibitory
anti–West Nile virus antibody is highly neutralizing
because it blocks fusion and delivers virus to the lysosome
for destruction.
A Neutralizing Anti-WNV MAb That Blocks Fusion
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fusion, WNV was pre-bound to Vero cells at 4uC, and
subsequently incubated on ice with saturating concentrations of
E16 IgG, E16 single chain Fv (scFv), E60 IgG, or no MAb. Cells
were warmed to 37uC in pH 5.5 media (or pH 7.5 media as a
negative control) to induce virus-plasma membrane fusion and
analyzed at 24 hours for level of infection by flow cytometry. In all
experiments, 10 nM concanamycin A1 was added to inhibit
infection via the canonical receptor-mediated endocytic pathway.
As expected, in the absence of antibody, addition of media at
neutral pH (7.5) did not promote productive infection (,0.7%
WNV antigen
+ cells, Figure 3A and 3B). Exposure of cell bound
WNV to media at pH 5.5 resulted in a ,7 fold increase in
infection (,5.1% WNV antigen
+ cells, P,0.0005, Figure 3A and
3B). The addition of E60 following viral attachment did not
appreciably affect virus-plasma membrane fusion (P=0.4),
confirming earlier results that this MAb does not inhibit Vero
cell infection at a post-attachment step [27]. In contrast, both E16
IgG and scFv efficiently blocked WNV-plasma membrane fusion
(0.15% and 0.08% WNV antigen
+ cells, respectively; Figure 3A
and 3B, P,0.0001).
E16 blocks pH-dependent fusion of WNV with liposomes
To confirm that E16 blocks membrane fusion of WNV, we
evaluated the fusogenic properties of WNV in a model liposome
system. To this end, WNV particles were metabolically labeled
with pyrene hexadecanoic acid and purified by density gradient
centrifugation. Subsequently, pyrene-labeled virions were pre-
incubated with various concentrations of E16, E60 or E111 (a
DIII-specific non-neutralizing control MAb [24]) and mixed with
liposomes. The mixture was acidified to pH 5.4 and fusion was
measured on-line in a fluorimeter at 37uC as a function of the
decrease in pyrene excimer fluorescence. WNV fuses rapidly and
efficiently with liposomes. In contrast, no membrane fusion
activity was measured with saturating concentrations of E16
(Figure 4A). Inhibition of membrane fusion by E16 was dose-
dependent as decreasing concentrations of E16 blocked fusion to a
lesser degree (Figure 4A and 4B). E111 did not influence the
membrane fusion properties of WNV as efficient fusion was
measured at all antibody concentrations tested. MAb E60 was
observed to induce a dose-dependent inhibition of membrane
fusion activity, although a complete inhibition of fusion was not
achieved (Figure 4B).
Figure 1. E16-opsonized WNV enters Vero cells. (A) Vero cells were incubated with WNV at an MOI of 100 in the presence or absence of 100 mg/
ml Alexa 488-E16 or E53 MAbs. Lysotracker red (50 nM) was added to the cells for the last 30 min of the incubation prior to paraformaldehyde
fixation. Green staining indicates Alexa 488 conjugated anti-WNV MAbs (panels B, F, J, and N), red staining indicates lysotracker red dye (panels C, G,
K, and O), and yellow staining represents co-localization as reflected by the merged images (panels D, H, L, and P). Cells were incubated for 2 h on ice,
washed, fixed, and observed by confocal microscopy (panels A–H). Cells were shifted to 37uC following the incubation on ice, fixed after 15 min and
observed by confocal microscopy (panels I–P). White arrows indicate examples of co-localization of anti-WNV MAbs and lysotracker red dye. (B) Cells
were infected for 3 h at 37uC in the presence of 100 mg/ml E16 (B, D) or E53 (panels F and H) and lysotracker dye (panels C, D, G, and H) fixed, and
analyzed by confocal microscopy. The scale bars represent 10 mm.
doi:10.1371/journal.ppat.1000453.g001
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WNV
Previous studies have shown that exposure of WNV or other
flaviviruses to acidic (pH,6) media in the absence of target
membranesresultsinEproteinrearrangement,prematureexposure
of the fusion loop, virus aggregation, and rapid irreversible
inactivation of fusion competence [36–38]. We reasoned that if
E16 neutralized WNV infection by directly blocking the pH-
dependent fusion event it should prevent adventitious inactivation
in solution after exposure to acidic pH. To test this, WNV (3610
3
PFU) was pre-incubated with saturating (100 mg/ml) concentrations
of E16, E60, or E9 (a DIII non-neutralizing MAb [24]) Fab
fragments. Although the E60 MAb did not appear to enter cells or
potently neutralize WNV infection [39], we included this fusion
loop-specific Fab as a control because it partially inhibited pH-
catalyzed virus fusion in the liposome assay. Excess buffered media
at pH 7.5 or pH 5.5 was added to the virus-Fab complexes and
incubated at 37uC for 15 min. The solution was normalized after
dilution with a 25-fold excess of pH 7.5 media and added to Vero
cells for 1 h at 37uC to allow infection as the monovalent Fab
fragments detached. As expected, exposure to a pH 7.5 solution did
notchangeWNVinfectivity,asthemonolayercontained,3.9610
3
PFU (Figure 5). In contrast, treatment with a pH 5.5 solution
inactivated WNV and reduced infectivity (P,0.0001) below the
limit of detection (,20 plaques). The E9 Fab failed to protect the
virus fromlowpH inactivation,whereas neutralizing concentrations
of E16 and E60 Fabs at pH 5.5 partially protected WNV from pH-
induced inactivation as 2.2 and 8.2610
2 PFU were detected,
respectively (Figure 5; P,0.05 and P,0.0001).
Because less infectious virus was detected with E16 compared to
E60 treatment following pH normalization and dilution, we
hypothesized that even a small number of bound E16 Fab could
still inhibit infectivity since this MAb requires a low fractional
occupancy for efficient neutralization [26]. Conversely, even
detachment of a few E60 Fabs could significantly increase
infectivity because virtually complete occupancy is required for
neutralization by this MAb [40]. Experiments were repeated and
excess recombinant E protein DIII (0.4 mg/ml) was added at the
time of pH normalization and dilution to compete off additional
bound E16 Fab. The addition of excess recombinant DIII further
increased WNV infectivity by ,4 fold (data not shown),
presumably by lowering the number of bound E16 Fab on some
virions below the threshold for neutralization. Overall, these
experiments show that saturating concentrations of both E16 and
E60 Fabs at least, partially prevent irreversible pH-dependent
inactivation of WNV in the absence of target membranes.
Discussion
Antibody neutralization is essential for protection against
infection by many viruses. A greater understanding of the
mechanism(s) by which the most strongly neutralizing antibodies
act could facilitate strategies for generating targeted vaccines and
immunotherapies. To establish the mechanism of action of E16, a
strongly neutralizing anti-WNV MAb with therapeutic potential,
we performed a series of cellular and biochemical experiments.
Cell biology studies demonstrate that E16 blocks WNV infection
at a post-entry stage by sequestering the virus in acidic
compartments and preventing its egress into the cytoplasm.
Biochemical experiments demonstrate that E16 neutralizes
WNV by directly blocking the pH-dependent fusion process.
Thus, the inhibitory activity of E16 against WNV in vivo is likely
defined by its ability to block viral fusion and nucleocapsid
penetration into the cytoplasm where replication occurs.
Figure 2. Blockade of endosomal acidification with concanamycin A1 mimics treatment with E16. Vero cells were infected at an MOI of
100 in the presence of 10 nM concanamycin A1 (panels A and D) or 100 mg/ml hE16 (panels B, C, E, and F) for 3 h (panels A–C) or 24 h (panels D–F)
and then fixed. Cells were then stained with a pool of Alexa-488 conjugated mouse anti-E MAbs (blue; A-F) and Alexa-647-conjugated goat anti-
human IgG (red; C and F) as indicated. Cells were analyzed by confocal microscopy. The white arrows indicate co-localization of hu-E16 and the
oligoclonal pool of mouse anti-E MAbs. Representative images are shown from one of two independent experiments. The images were analyzed
using the LSM510 confocal microscopy software to assess the overlap in staining. Because of the overlay appearance, we converted the fluorescence
images into blue (Alexa-488) and red (Alexa-647) colors for Figure display. The scale bars represent 10 mm.
doi:10.1371/journal.ppat.1000453.g002
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protein led to a hypothesis that E16 blocked the structural
rearrangement required for fusion at low pH [27]. Indeed, E16
engages a large solvent-exposed surface of DIII, a domain that is
positioned distinctly in the pre- and post-fusion E protein
conformations [10]. The biochemical data presented here
demonstrating that E16 Fab blocks the pH-dependent inactivation
of WNV in solution is consistent with a direct inhibition of the
structural transition of E protein that occurs during fusion.
Nonetheless, definitive evidence of this structural mechanism
Figure 3. E16 scFv or IgG blocks infection in a plasma membrane fusion assay. WNV (10
6 PFU) was bound to Vero cells for 2 h on ice after
pretreatment with 10 nM concanamycin A1. Subsequently, media, 100 mg/ml E16 IgG, E16 scFv or E60 IgG was added for 30 min on ice, and then the
pH shifted at 37uC to pH 7.5 or pH 5.5 for ,7 min. Cells were washed, the pH normalized, incubated at 37uC for ,18 h, permeabilized and stained
with an oligoclonal pool of anti-E MAbs. The level of infection was assessed by flow cytometry. (A) Representative flow cytometric histogram plots
from each condition are shown. The plots are gated to show the percentage of cells that stained positive with an anti-WNV E MAb. The treatment and
percentage of positive cells are shown in the top right corner of each plot. (B) The data averaged from three independent experiments is shown with
error bars indicating standard deviations. Statistically significant differences between different experimental conditions are described in the text.
doi:10.1371/journal.ppat.1000453.g003
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microscopy in media at acidic pH.
In surface plasmon resonance (SPR) binding studies, E16 bound
DIII of the WNV E protein with similar affinity across a range of
pH values from pH 5 to pH 8 (B.S. Thompson, M.S. Diamond
and D.H. Fremont, unpublished data). This explains why the
binding and neutralizing activity of E16 is not altered as the virus-
MAb complex transits through the endosomal compartments.
Indeed, the confocal microscopy experiments showed co-localiza-
tion of E16 and virus through acidic compartments into the
lysosome. Our investigations with MAbs are consistent with an
earlier study showing a strongly neutralizing polyclonal serum
against WNV inhibited at a post-attachment step [41]; the authors
of that study speculated but did not show that the most potently
inhibitory antibodies block viral fusion. One reason why antibody
blockade of fusion may be particularly potent in vivo for
flaviviruses is because it acts downstream of an increasing number
of cellular attachment factors (e.g., DC-SIGN, DC-SIGNR,
heparin sulfate, Fc-c receptors, and avb3 integrin [42–45]).
The confocal microscopy experiments also suggest that E16-
opsonized WNV is retained in acidic compartments that are
ultimately targeted for degradation. Antibodies like E16 that block
fusion may be particularly potent at clearing viral infection in vivo
because in addition to directly limiting transit to and replication in
the cytoplasm they effectively convert permissive cells into ones
that target virus for destruction. This feature of E16, along with its
ability to disrupt transneuronal spread [46], high affinity, and
capacity to neutralize at low virion occupancy [26], begins to
explain its single-dose potent post-exposure therapeutic activity in
animals [24,47].
The mechanistic analysis of E16 and WNV is supported by
recent studies with MAbs against DIII of TBEV, some of which
also blocked fusion of pyrene-labeled virus with liposomes [48].
Nonetheless, it remains unclear if the DIII MAbs against TBEV
have equivalent neutralizing capacity and bind the same structural
epitope as E16. The TBEV study also showed that DII-fusion loop
MAbs were effective at blocking liposomal fusion. Although we
also observed efficient dose-dependent inhibition of membrane
fusion with E60, approximately one-third of the virus particles
remained fusion competent even under conditions of antibody
excess. This data is consistent with our observation that E53 and
E60 are less strongly inhibitory MAbs against WNV [39] and that
heterogeneity of WNV particles with respect to their state of
maturation (mostly immature, partially mature, or fully mature)
affects the ability of fusion loop MAbs to bind and neutralize
infection [40]. As the fusion loop epitope is poorly accessible on
the mature WNV virion [13,40,49], E53 and E60 MAbs require a
relatively high fractional occupancy to inhibit infection [40].
Indeed, they may not achieve sufficient MAb concentration in the
Figure 4. E16 blocks low pH-induced fusion of WNV with liposomes. Fusion of pyrene-labeled WNV with liposomes at pH 5.4. Fusion was
measured in real-time as described in the Materials and Methods. (A) (a) no antibody; (b) 0.1 nM E16; (c) 1 nM E16; and (d) 50 nM E16. Representative
viral fusion curves are from at least three independent experiments. (B) Effect of different concentrations of MAbs on WNV-liposome fusion. The WNV-
liposome fusion profiles are shown as a percentage of the control (pH 5.4, without MAbs). Black bars, E16; gray bars, E60; and white bars, E111. Data
are expressed as the mean of at least three independent experiments and the error bars indicate standard deviations.
doi:10.1371/journal.ppat.1000453.g004
Figure 5. E16 Fab protects WNV from pH-induced inactivation
in solution. WNV (3610
3 PFU) was incubated alone in the presence of
media, 100 mg/ml E16 Fab, E60 Fab or E9 Fab for 30 min on ice. The
reaction was diluted 5-fold in media at pH 7.5 or pH 5.5 and incubated
at 37uC for 15 min, and then back-neutralized with a 25-fold excess of
media at pH 7.5. This mixture was added to a monolayer of Vero cells
prior to an overlay with 2% agarose. Three days later, plaques were
fixed and scored. The dotted line represents the lower limit of detection
the assay (2610
1 PFU). Data is expressed as the mean of three separate
experiments performed in duplicate. Statistical significance is indicated
in the graph and was calculated using a two-tailed paired t test.
doi:10.1371/journal.ppat.1000453.g005
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Vero cells, our data with E53 and E60 suggests that antibodies of
this class block at a proximal attachment step [27]. Based on these
observations, we have developed a model for how the DII-fusion
loop and DIII-lateral ridge MAbs neutralize WNV infection
(Figure 6).
Blockade of viral fusion by antibodies or pharmacologic agents
is usually considered as a therapeutic strategy for viruses that fuse
with the plasma membrane. For example, enfuvirtide (Fuzeon
TM
or T-20 peptide) effectively inhibits entry of HIV at the plasma
membrane of CD4
+ T cells by interfering with the requisite
structural transition that brings viral and cell surfaces into
proximity for fusion (reviewed in [50]). In contrast, there have
been relatively few descriptions of antibodies that neutralize
flaviviruses by blocking endosomal fusion. Butrapet et al described
an anti-Japanese encephalitis virus antibody (MAb 503) that
inhibited fusion-induced syncytia of infected insect cells and virus
internalization into Vero cells. Although they concluded that this
MAb functioned at a step post-attachment, they did not clearly
demonstrate that it directly blocked fusion [51]. Similarly, the
mechanism of action of the potently neutralizing anti-DENV2
MAb, 3H5-1 [52], has been speculated. Whereas He et al, showed
that 3H5-1 blocked attachment of DENV2 to Vero cells [53], Se-
Thoe et al, using LLC-MK2 cells, concluded that 3H5-1 primarily
blocked the DENV2 fusion at the plasma membrane [54]. We
recently localized the epitope of 3H5-1 of DENV2 to residues in
the N-terminal region and FG loops of the lateral ridge of DIII, in
an analogous position to that for E16 and WNV DIII [55].
Although further studies are necessary, based on structural
localization and functional potency, we speculate that 3H5-1
and other strongly neutralizing DIII lateral ridge MAbs inhibit
flavivirus infections, at least in part through similar fusion blocking
mechanisms.
In summary, our experiments define the mechanism of action of
a potently inhibitory therapeutic antibody against WNV. E16
prevents egress of WNV from endosomes, leading to retention in
Figure 6. Model of anti–WNV MAb neutralization. The neutralization of WNV infection in Vero cells occurs by different mechanisms depending
on the epitopes occupied by the MAbs. WNV infection in the absence of antibodies results in attachment, endocytosis, fusion, uncoating and release
of the viral RNA into the cytoplasm. Vero cell infection in the presence of neutralizing concentrations of the fusion loop MAbs E53 or E60 results in a
blockade in viral attachment. In contrast, infection in the presence of E53 or E60 at sub-neutralizing concentrations allows for efficient attachment,
entry, fusion and infection. Infection in the presence of neutralizing concentrations of E16 or E24 (which require lower fractional occupancy for
neutralization) results in relatively normal attachment and endocytosis. However, these MAbs inhibit fusion of the viral membrane with the
endosomal membrane leading to subsequent targeting of the virus particles to the lysosome.
doi:10.1371/journal.ppat.1000453.g006
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lysosome. Vaccines that skew the immune response towards
production of antiviral antibodies that inhibit fusion may improve
protection against challenge. For highly promiscuous viruses like
flaviviruses, targeting of the endosomal fusion step may be
particularly relevant given the discovery of increasing numbers
of distinct entry pathways on mammalian cells [42,43].
Materials and Methods
Cell culture and propagation of WNV
Vero cells were used for confocal microscopy experiments, the
plasma membrane fusion assay, and to titrate infectious virus by
plaque assay. Vero cells were grown in Dulbecco’s modified
eagle’s medium (DMEM) supplemented with 10% FBS, 10 mM
HEPES and 1% penicillin/streptomycin, as described [56]. WNV
(strain 3000.0259, New York, 2000) [57] was propagated in C6/
36 Aedes albopictus cells, aliquotted, and frozen at 280uC.
Pyrene-labeled virus particles
Pyrene-labeled WNV was isolated from the medium of infected
BHK21 cells that was cultured in the presence of 15 mg/ml of 16-
(1-pyrenyl)-hexadecanoic acid (Invitrogen, Breda, The Nether-
lands), essentially as described before for alphaviruses [58,59].
BHK21 cells were infected at a MOI of 4. At 24 h post-infection,
the supernatant was harvested and pyrene-labeled WNV particles
were pelleted by ultracentrifugation (Beckman type 19 rotor; 15 hr
at 48,5006ga t4 uC). Subsequently, the virus particles were
purified on an Optiprep (Axis-Shield, Oslo, Norway) density (15–
55% w/v) gradient by ultracentrifugation (Beckman SW41 rotor;
18 hr at 100,0006ga t4 uC). The infectivity of the virus
preparation was determined by titration on BHK21-15 cells.
Protein concentration was determined by micro-Lowry analysis.
Preparation of liposomes
Large unilamellar vesicles were prepared by a freeze/thaw
extrusion procedure as described [59]. Liposomes consisted of
phosphatidylcholine (PC) from egg yolk, phosphatidylethanol-
amine (PE) prepared by transphosphatidylation of egg PC, and
cholesterol in a molar ratio of 1:1:2. Liposomes were prepared
with an average size of 200 nm. All lipids were obtained from
Avanti Polar Lipids (Alabaster, AL).
Antibodies and flow cytometry
The anti-WNV antibodies E9, E16, E24, E53, E60, and E111
have been previously described [24,27,39]. Fab fragments were
generated by papain digestionand purified by protein A affinity and
size exclusion chromatography as described [27]. The generation
and purificationoftheE16scFv will be described in detailelsewhere
(B. Kauffman, S. Johnson, D. Fremont, M. Diamond, and M.
Rossmann,manuscriptin preparation). DirectconjugationofMAbs
to fluorochromes was performed using an Alexa FluorH 488 (or 647)
MAb labeling kit (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Both anti-human and anti-mouse
secondary antibodies conjugated to fluorochromes were purchased
(Invitrogen) and used at a 1:200 dilution for confocal microscopy
and flow cytometry.Flow cytometricanalysis wasperformed usinga
BD FACS Calibur and BD Cellquest Pro
TM software (Becton
Dickinson, San Jose, CA).
Virus binding assays and confocal microscopic analysis
Vero cells were plated at ,7,500 cells/well in 8-well Lab-Tek
chambered slides (Nunc, Rochester, NY) and incubated overnight.
The cells were infected with WNV (MOI of 100) in the presence or
absence of Alexa-488 conjugated antibodies at the indicated
temperature and time, washed with PBS, and fixed with 2%
paraformaldehyde in PBS for 30 min at room temperature.
Acidified endosome and lysosome compartments were identified
with Lysotracker red (Invitrogen) by adding the dye (50 nM) to the
cells for the last 30 min of the incubation prior to fixation.
To assess whether blockade of endosomal acidification mimics
treatment with E16, Vero cells were infected at an MOI of 100 in
the presence of 10 nM concanamycin A1 or 100 mg/ml hE16 for 3
h or 24 h, fixed with 2% paraformaldehyde, and permeabilized
with PBS supplemented with 0.1% saponin. Cells were stained
with a pool of Alexa-488 conjugated mouse anti-E MAbs and in
some experiments, Alexa-647-conjugated goat anti-human IgG.
After extensive washing and fixation, cells were analyzed by
confocal microscopy using a Zeiss LSM510 META Laser
Scanning Confocal Microscope (Carl Zeiss Inc., Thornwood,
NY) as described [60]. Images were analyzed using the LSM510
software suite and Volocity
TM software package (Improvision Inc.,
Waltham, MA).
Plasma membrane fusion assay
The assay for plasma membrane fusion of flaviviruses has been
described previously [32]. We adapted the protocol to test the
effects of MAbs on WNV fusion at the plasma membrane. Briefly,
Vero cells were plated in 12 well plates at 5610
4 cells per well and
incubated for 24 h at 37uC. The cells were then pre-incubated
with 10 nM concanamycin A1 for 30 min. WNV (MOI of 100)
was complexed with 100 mg/ml E16 IgG, E16 scFv, E60 IgG or
control medium for 30 min at 4uC and bound to Vero cells for 2 h
on ice. Subsequently, cells were washed twice with iced PBS and
pre-warmed DMEM (buffered to pH 5.5 or pH 7.5) was added at
37uC for ,7 min. The cells were then washed with PBS and
incubated for 24 h at 37uC in DMEM containing 10 nM
concanamycin A1, which blocks virus fusion after receptor
mediated entry pathways. The cells were washed twice in PBS
and fixed in PBS with 2% paraformaldehyde, permeabilized with
0.1% saponin and stained with an oligoclonal pool of Alexa Fluor-
488-labeled anti-WNV MAbs. Samples were processed by flow
cytometry and data was analyzed using the Cellquest Pro
TM
software.
pH inactivation assay in solution
WNV (,3610
3 PFU) was incubated alone or with 100 mg/ml
E16 Fab, E60 Fab or E9 Fab in DMEM at neutral pH for 30 min
at 4uC. The reactions were then diluted 5-fold in DMEM
supplemented with 20 mM succinic acid (pH 5.5) or 20 mM
HEPES (pH 7.5) and incubated at 37uC for 15 min. Each reaction
was subsequently neutralized by a 25-fold dilution in DMEM at
pH 7.5 and added to a monolayer of Vero cells in a 6 well plate for
1 h at 37uC. Following this incubation, the cells were overlaid with
2% low melting agarose and a standard plaque assay was
performed. In some experiments, recombinant DIII (0.4 mg/ml)
purified from E. coli [27] was added at the time of 25-fold dilution
to compete bound Fabs.
WNV–liposome fusion assay
Fusion of pyrene-labeled WNV with PE/PC/cholesterol (molar
ratio of 1:1:2) liposomes was monitored continuously in a
Fluorolog 3–22 fluorometer (BFi Optilas, Alphen aan den Rijn,
The Netherlands), at excitation and emission wavelengths of 345
nm and 480 nm. Pyrene-labeled WNV (0.35 mg protein;
corresponds to 1.5610
10 particles) and an excess of liposomes
(140 nmol phospholipid; corresponds to 3610
10 liposomes) was
mixed in a final volume of 0.665 ml in 5 mM HEPES pH 7.4, 150
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magnetically at 37uC. At t=0 sec, the pH of the medium was
adjusted to 5.4 by addition of 35 ml 0.1 MES, 0.2 M acetic acid,
pre-titrated with NaOH to achieve the final desired pH. The
fusion scale was calibrated such that 0% fusion corresponded to
the initial excimer fluorescence value. The 100% value was
obtained through the addition of 35 ml 0.2 M octaethyleneglycol
monododecyl ether (Fluka Chemie AG, Buchs, Switzerland) to
achieve an infinite dilution of the probe. The extent of fusion was
determined 60 seconds after acidification. To analyze the influence
of E16, E60, and E111 on WNV fusion, pyrene-labeled WNV was
incubated with increasing concentrations of MAbs for 1 hr at 20uC
prior to mixing with liposomes.
Supporting Information
Figure S1 Cells were infected with WNV in the absence of
MAbs for (A) 3, (B) 6, and (C) 24 hours as indicated, fixed, stained
with an oligoclonal mixture of anti-E MAbs, and analyzed by
confocal microscopy. Representative images are shown from one
of at least four independent experiments.
Found at: doi:10.1371/journal.ppat.1000453.s001 (3.22 MB TIF)
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